Latest From 23andMe Inc.
A couple of years after Ipsen returned the rights to an LRRK2 Parkinson's program, Oncodesign has bagged a new partner in Servier and stands to bank up to €320m if all goes well.
Femtech, which describes digital technologies that aim to improve women's health, is expected to reach $50bn in market size by 2025, according to Frost & Sullivan. Reproductive health and menstrual health trackers are two of the fastest-growing sectors in femtech. We've highlighted some of the biggest players in both segments, their innovative business models, plans and also looked at barriers such as privacy issues, accuracy of mobile applications and funding challenges.
It was another record year for novel device approvals by US FDA, driven by the big uptick in de novo classifications for low-to-moderate-risk devices in 2018. Meanwhile, original PMA approvals dropped significantly. An analysis and infographic on FDA device approval trends in 2018.
It is time for In Vivo's 11th annual Deals of the Year contest. We've selected 18 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Saliva-based Testing
- Laboratory Testing Services
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- 23andMe Inc.
- Senior Management
Anne Wojcicki, CEO
Dean Schorno, CFO & Head, Operations
Richard Scheller, PhD, CSO & Head, Therapeutics
Joyce Tung, PhD, VP, Research
Steve Lemon, VP, Product & Engineering
Kathy Hibbs, JD, Chief Legal & Regulatory Officer
Emily Drabant Conley, PhD, VP, BD
Robert Gentleman, PhD, VP, Computational Biology
Jonathan Ward, VP, Consumer Marketing & Acquisition
Tracy Keim, MS, VP, Consumer Marketing & Brand
- Contact Info
Phone: (650) 938-6300
899 West Evelyn Avenue
Mountain View, CA 94041
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.